New biochemical markers of bone turnover in osteoporosis;Nouveaux marqueurs biologiques du remodelage osseux dans l'ostéoporose

Medecine Nucleaire

Volumn 33, Issue 1, 2009, Pages 17-27

  Garnero, P ^a  

^a INSERM   (France)

Author keywords

Biochemical markers; Bisphosphonate; Collagen; Fracture; Osteoporosis

Indexed keywords

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; ALENDRONIC ACID; ASPARTIC ACID; BIOLOGICAL MARKER; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CARBOXY TERMINAL TELOPEPTIDE; CATHEPSIN K; COLLAGEN; ESTRADIOL; IBANDRONIC ACID; ISOENZYME; OSTEOCALCIN; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PAMIDRONIC ACID; PARATHYROID HORMONE; RALOXIFENE; RISEDRONIC ACID; SIALOPROTEIN; WNT PROTEIN; ZOLEDRONIC ACID;

BONE CELL; BONE DENSITY; BONE MATRIX; BONE METABOLISM; BONE REMODELING; BONE TURNOVER; CELL FUNCTION; CROSS LINKING; FRACTURE; GLYCATION; HUMAN; ISOMERIZATION; OSTEOBLAST; OSTEOCLAST; OSTEOLYSIS; OSTEOPENIA; OSTEOPOROSIS; POSTMENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS; PROTEIN MODIFICATION; PROTEIN PROCESSING; RISK ASSESSMENT; SHORT SURVEY;

EID: 58949087526     PISSN: 09281258     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mednuc.2008.09.008     Document Type: Short Survey

References (83)

1. Garnero P., Ferreras M., Karsdal M.A., Nicamhlaoibh R., Risteli J., Borel O., et al. The type I collagen fragments ICTP and CTX reveal distinct enzymatic pathways of bone collagen degradation. J Bone Miner Res 18 (2003) 859-867
2. Garnero P., Shih W., Gineyts E., Karpf D., and Delmas P.D. Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment. J Clin Endocrinol Metab 79 (1994) 1693-1700
3. Blomqvist C., Risteli L., Risteli J., Virkkunen P., Sarna S., and Elomaa I. Markers of type I collagen degradation and synthesis in the monitoring of treatment responses in bone metastases from breast cancer. Br J Cancer 73 (1996) 1074-1079
4. Kylmälä T., Tammela T.L.J., Risteli L., Risteli J., Kontturi M., and Elomaa I. Type I collagen degradation product (ICTP) gives information about the nature of bone metastases and has prognostic value in prostate cancer. Br J Cancer 71 (1995) 1061-1064
5. Garnero P., and Delmas P.D. An Immunoassay for type I collagen alpha 1 helicoidal peptide 620-633, a new marker of bone resorption in osteoporosis. Bone 32 (2003) 20-26
6. Halleen J.M., Karp M., Viloma S., Hellman J., Käkönen S.M., Stepan J.J., et al. Two-site immunoassays for osteoclastic tartrate-resistant acid phosphatase based on characterization of six monoclonal antibodies. J Bone Miner Res 14 (1999) 464-469
7. Halleen J.M., Ylipahkala H., Alatalo S.L., Janckila A.J., Heikkinen J.E., Suominen H., et al. Serum tartrate resistant acid phosphatase 5b, but not 5a, correlates with other markers of bone turnover and bone mineral density. Calcif Tissue Int 71 (2002) 20-25
8. Ohashi T., Igarashi Y., Mochizuki Y., Miura T., Inaba N., Katayama K., et al. Development of a novel fragments absorbed immunocapture enzyme assay system for tartrate-resistant acid phosphatase 5b. Clin Chim Acta 376 (2007) 205-212
9. Halleen J.S., Alatalo S.L., Suominen H., Cheng S., Janckila A.J., and Väänänen H.K. Tartrate-resistant acid phosphatase 5b: a novel serum marker of bone resorption. J Bone Miner Res 15 (2000) 1337-1345
10. Nenonen A., Cheng S., Ivaska K.K., Alatalo S.L., Lehtimäki T., Schmidt-Gayk H., et al. Serum TRACP 5b is a useful marker for monitoring alendronate treatment: comparison with other markers of bone turnover. J Bone Miner Res 20 (2005) 1804-1812
11. Hannon R.A., Clowes J.A., Eagleton A.C., Hadari A.A., Eastell R., and Blumsohn A. Clinical performance of immunoreactive tartrate-resistant acid phosphatase isoform 5b as a marker of bone resorption. Bone 34 (2004) 187-194
12. Meier C., Meinhardt U., Greenfield J.R., De Winter J., Nguyen T.V., Dunstan C.R., et al. Serum cathepsin K concentrations reflect osteoclast activity in women with postmenopausal osteoporosis and patients with Paget's disease of bone. Clin Lab 21 (2006) 1-10
13. Skoumal M., Haberhauer G., Kolarz G., Hawa G., Woloszczuk W., and Klingler A. Serum cathepsin K levels of patients with longstanding rheumatoid arthritis: correlation with radiological destruction. Arthritis Res Ther 7 (2005) R65-R70 [Epub 2004]
14. Garnero P., Grimaux M., Seguin P., and Delmas P.D. Characterization of immunoreactive forms of human osteocalcin generated in vivo and in vitro. J Bone Miner Res 9 (1994) 255-264
15. Ivaska K.K., Hentunen T.A., Vaaraniemi J., Ylipahkala H., Pettersson K., and Väänänen H.K. Release of intact and fragmented osteocalcin molecules from bone matrix during bone resorption in vitro. J Biol Chem 279 (2004) 18361-18369
16. Srivastava A.K., Mohan F.R., Singer F.R., and Baylink D.J. A urine midmolecule osteocalcin assay shows higher discriminatory power than a serum midmolecule osteocalcin assay during short-term alendronate treatment of osteoporotic patients. Bone 31 (2002) 62-69
17. Ivaska K.K., Hellman J., Likojarvi J., Kakonen S.M., Gerdhem P., Akesson K., et al. Identification of novel proteolytic forms of osteocalcin in human urine. Biochem Biophys Res Commun 306 (2003) 973-980
18. Ivaska K.K., Kakonen S.M., Gerdhem P., Obrant K.J., Pettersson K., and Väänänen H.K. Urinary osteocalcin as a marker of bone metabolism. Clin Chem 51 (2005) 618-628
19. Ivaska K.K., Pettersson K., Nenonen A., Uusi-Rasi K., Heinonen A., Kannus P., et al. Urinary osteocalcin is a useful marker for monitoring the effect of alendronate therapy. Clin Chem 51 (2005) 2362-2365
20. Gerdhem P., Ivaska K.K., Alatalo S.L., Halleen J.M., Hellman J., Isaksson A., et al. Biochemical markers of bone metabolism and prediction of fracture in elderly women. J Bone Miner Res 19 (2004) 386-393
21. Papotti M., Kalebic T., Volante M., Chiusa L., Bacillo E., Cappia S., et al. Bone sialoprotein is predictive of bone metastases in resectable non-small-cell lung cancer: a retrospective case-control study. J Clin Oncol 24 (2006) 4818-4824
22. Seibel M., Woitge H., Pecherstorfer M., Karmatschek M., Horn E., Ludwig H., et al. Serum immunoreactive bone sialoprotein as a new marker of bone turnover in metabolic and malignant bone disease. J Clin Endocrinol Metab 81 (1996) 3289-3294
23. Woitge H.W., Pecherstorfer M., Horn E., Keck A.V., Diel I.J., Bayer P., et al. Serum bone sialoprotein as a marker of tumour burden and neoplastic bone involvement and as a prognostic factor in multiple myeloma. Br J Cancer 84 (2001) 344-351
24. Diel I.J., Solomayer E.F., Seibel M.J., Pfeilschifter J., Maisenbacher H., Gollan C., et al. Serum bone sialoprotein in patients with primary breast cancer is a prognostic marker for subsequent bone metastasis. Clin Cancer Res 5 (1999) 3914-3919
25. Rogers A., and Eastell R. Circulating osteoprotegerin and receptor activator for nuclear factor kappaB ligand: clinical utility in metabolic bone disease assessment. J Clin Endocrinol Metab 90 (2005) 6323-6331
26. Tian E., Zhan F., Walker R., Rasmussen E., Ma Y., Barlogie B., et al. The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med 349 (2003) 2483-2494
27. Voorzanger-Rousselot N., Goehrig D., Journe F., Doriath V., Body J.J., Clézardin P., et al. Increased Dickkopf-1 expression in breast cancer bone metastases. Br J Cancer 97 (2007) 964-970
28. Diarra D., Stolina M., Polzer K., Zwerina J., Ominsky M.S., Dwyer D., et al. Dickkopf-1 is a master regulator of joint remodeling. Nat Med 13 (2007) 156-163
29. Garnero P, Charni Ben-Tabassi N, Rousselot N. Circulating Dickkopf-1 and radiological progression in patients with early rheumatoid arthritis treated with etanercept. J Rheumatol (sous presse).
30. Lane N.E., Nevitt M.C., Lui L.Y., de Leon P., Corr M., and Study of Osteoporotic Fractures Research Group. Wnt signaling antagonists are potential prognostic biomarkers for the progression of radiographic hip osteoarthritis in elderly Caucasian women. Arthritis Rheum 56 (2007) 3319-3325
31. Dominguez L.J., Barbagallo M., and Moro L. Collagen overglycosylation: a biochemical feature that may contribute to bone quality. Biochem Biophys Res Com 330 (2005) 1-4
32. Viguet-Carrin S., Garnero P., and Delmas P.D. The role of collagen in bone strength. Osteoporos Int 17 (2006) 319-336
33. Kirsh E., Krieg T., Remberger K., Fendel H., et al. Disorder of collagen metabolism in a patient with osteogenesis impefecta (lethal type): increased degree of hydroxylation of lysine in collagen type I and type III. Eur J Clin Invest 11 (1981) 39-47
34. Sims T.J., Momles C.A., Bailey A.J., and Camacho N.P. Properties of collagen in oim mouse tissues. Connect Tissue Res 44 Suppl. 1 (2003) 202-205
35. Bailey A.J., Wotton S.F., Sims T.J., and Thompson P.W. Post-translational modifications in the collagen of human osteoporotic femoral head. Biochem Biophys Res Commun 185 (1992) 801-805
36. Batge B., Deibold J., Stein H., Bodo M., and Müller P.K. Compositional analysis of the collagenous bone matrix: a study on adult normal and osteopenic bone tissue. Eur J Clin Invest 22 (1992) 805-812
37. Kowitz J., Knippel M., Schuhr T., and Mach J. Alteration in the extent of collagen I hydroxylation, isolated from femoral heads of women with a femoral neck fracture caused by osteoporosis. Calcif Tissue Int 60 (1992) 501-505
38. Oxlund H., Moselkilde L., and Ortoft G. Reduced concentration of collagen reducible cross-links in human trabecular bone with respect to age and osteoporosis. Bone 19 (1996) 479-484
39. Saito M., Marumo K., Fujii K., and Ishioka N. Single-column high performance liquid chromatographic fluorescence detection of immature, mature and senescent crosslinks of collagen. Anal Biochem 253 (1997) 26-32
40. Odetti P., Rossi S., Moancelli F., Poggi A., Cirnigliaro M., Federici M., et al. Advanced glycation end products and bone loss during aging. Ann N Y Acad Sci 1043 (2005) 710-717
41. Hein G., Weiss C., Lehmann G., Niwa T., Stein G., and Franke S. Advanced glycation end product modification of bone proteins and bone remodeling: hypothesis and preliminary immunohistochemical findings. Ann Rheum Dis 65 (2006) 101-104
42. Hein G., Wiegand R., Lehman G., Stein G., and Franke S. Advanced glycation end-products pentosidine and N epsilon carboxymethyllysine are elevated in serum of patients with osteoporosis. Rheumatology 42 (2003) 1242-1246
43. Saito M., Fujii L., Soshi S., and Tanaka T. Reductions in degree of mineralization and enzymatic collagen crosslinks and increases in glycation-induced pentosidine in the femoral neck cortex in cases of femoral neck fracture. Osteoporos Int 17 (2006) 986-995
44. Wang X., Shen X., Li X., and Agrawal C.M. Age-related changes in collagen network and toughness of bone. Bone 31 (2002) 1-7
45. Hernandez C.J., Tang S., Baumbach B.M., Hwu P.B., Sakkee A.N., van der Ham F., et al. Trabecular microfracture and the influence of pyridinium and non-enzymatic glycation-mediated collagen cross-links. Bone 37 (2005) 825-832
46. Viguet-Carrin S., Roux J.P., Arlot M.E., Merabet Z., Leeming D.J., Byrjalsen I., et al. Contribution of the advanced glycation end product pentosidine and of maturation of type I collagen to compressive biomechanical properties of human lumbar vertebrae. Bone 39 (2006) 1073-1079
47. Garnero P., Fledelius C., Gineyts E., Serre C.M., Vignot E., and Delmas P.D. Decreased β isomerisation of C-telopeptides of type I collagen in Paget's disease of bone. J Bone Miner Res 12 (1997) 1407-1415
48. Garnero P., Cloos P., Sornay-Rendu E., Qvist P., and Delmas P.D. Type I collagen racemization and isomerization and the risk of fracture in postmenopausal women: the OFELY prospective study. J Bone Miner Res 17 (2002) 826-833
49. Garnero P., Schott A., Meunier P.J., and Chevrel G. Impaired type I collagen C-telopeptide isomerization in patients with osteogenesis imperfecta. J Bone Miner Res 21 Suppl. 1 (2006) S429
50. Garnero P., Borel O., Gineyts E., Duboeuf F., Solberg H., Bouxsein M.L., et al. Extracellular post-translational modifications of collagen are major determinants of biomechanical properties of fetal bovine cortical bone. Bone 38 (2006) 300-309 [Epub 2005 Nov 3]
51. Byrjalsen I., Leeming D.J., Qvist P., Christiansen C., and Karsdal M.A. Bone turnover and bone collagen maturation in osteoporosis: effects of antiresorptive therapies. Osteoporos Int 19 (2008) 339-348
52. Karsdal M.A., Byrjalsen I., Leeming D.J., Delmas P.D., and Christiansen C. The effects of oral calcitonin on bone collagen maturation: implications for bone turnover and quality. Osteoporos Int 19 (2008) 1355-1361
53. Garnero P., Bauer D., Mareau E., Bilezikian J., Greenspan S., Rosen C., et al. Effects of parathyroid hormone and alendronate on Type I collagen isomerization in postmenopausal women with osteoporosis: the PaTH study. J Bone Miner Res 23 (2008) 1442-1448
54. Garnero P., Hausherr E., Chapuy M.C., Marcelli C., Grandjean H., Muller C., et al. Markers of bone resorption predict hip fracture in elderly women: the EPIDOS prospective study. J Bone Miner Res 11 (1996) 1531-1538
55. Johnell O., Oden A., De Laet C., Garnero P., Delmas P.D., and Kanis J.A. Biochemical markers and the assessment of fracture probability. Osteoporos Int 13 (2002) 523-526
56. Sornay-Rendu E., Munoz F., Garnero P., Duboeuf F., and Delmas P.D. Identification of osteopenic women at high risk of fracture: the OFELY Study. J Bone Miner Res 20 (2005) 1813-1819
57. McClung M.R., Geusens P., Miller P.D., Zippel H., Bensen W.G., Roux C., et al., Hip Intervention Program Study Group. Effect of risedronate on the risk of hip fracture in elderly women. New Engl J Med 344 (2001) 333-340
58. Kanis J.A., Johnell O., Black D.M., Downs Jr. R.W., Sarkar S., Fuerst T., et al. Effect of raloxifene on the risk of new vertebral fracture in postmenopausal women with osteopenia or osteoporosis: a reanalysis of the multiple outcomes of raloxifene evaluation trial. Bone 33 (2003) 293-300
59. Bauer D.C., Garnero P., Hochberg M.C., Santora A., Delmas P., Ewing S.K., et al., for the Fracture Intervention Research Group. Pre-treatment levels of bone turnover and the anti-fracture efficacy of alendronate: the fracture intervention trial. J Bone Miner Res 21 (2006) 292-299
60. Black D.M., Thompson D., Quandt S., Palermo L., et al. Alendronate reduces the risk of vertebral fracture in women with BMD T-scores above -2.5: results from the Fracture Intervention Trial (FIT). Osteoporos Int 13 Suppl. 1 (2002) S27
61. Delmas P.D., Licata A.A., Reginster J.Y., Crans G.G., Chen P., Misurski D.A., et al. Fracture risk reduction during treatment with teriparatide is independent of pretreatment bone turnover. Bone 39 (2006) 237-243
62. Bauer D.C., Garnero P., Bilezikian J.P., Greenspan S.L., Ensrud K.E., Rosen C.J., et al. Short-term changes in bone turnover markers and bone mineral density response to parathyroid hormone in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 91 (2006) 1370-1375
63. Chapurlat R.D., and Cummings S.R. Does follow-up of osteoporotic women treated with antiresorptive therapies improve effectiveness?. Osteoporos Int 13 (2002) 738-744
64. Clowes J.A., Peel N.F., and Eastell R. The impact of monitoring on adherence and persistence with antiresorptive treatment for postmenopausal osteoporosis: a randomized controlled trial. J Clin Endocrinol Metab 89 (2004) 1117-1123
65. Delmas P.D., and Garnero P. Utility of biochemical markers of bone turnover in osteoporosis. In: Marcus R., Feldman D., and Kelsey J. (Eds). Osteoporosis (1996), Academic Press, New York 1075-1085
66. Delmas P.D., Vrijens B., Eastell R., Roux C., Pols H.A., Ringe J.D., et al. Effect of monitoring bone turnover markers on persistence with risedronate treatment of postmenopausal osteoporosis. J Clin Endocrinol Metab 92 (2007 Apr) 1296-1304 [Epub 2007 Jan 23]
67. Garnero P., Tsouderos Y., Marton I., Pelissier C., Varin C., and Delmas P.D. Effects of intranasal 17β-estradiol on bone turnover and serum insulin-like growth factor I in postmenopausal women. J Clin Endocrinol Metab 84 (1999) 2390-2397
68. Garnero P., Gineyts E., Arbault P., Christiansen C., and Delmas P.D. Different effects of bisphosphonate and estrogen therapy on free and peptide-bound bone cross-links excretion. J Bone Miner Res 10 (1995) 641-649
69. Ho K.K.Y., and Weissenberg A.J. Impact of short-term estrogen administration on growth hormone secretion and action: distinct route-dependent effects on connective and bone tissue metabolism. J Bone Miner Res 7 (1992) 821-827
70. Reid I.R., Brown J.P., and Burckhardt P. Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med 346 (2002) 653-661
71. Black D.M., Schwartz A.V., Ensrud K.E., Cauley J.A., Levis S., Quandt S.A., et al., FLEX Research Group. Effects of continuing or stopping alendronate after five years of treatment: the fracture intervention trial long-term extension (FLEX): a randomized trial. JAMA 296 (2006) 2927-2938
72. Devogelaer J.P., Brown J.P., Burckhardt P., Meunier P.J., Goemaere S., Lippuner K., et al. Zoledronic acid efficacy and safety over five years in postmenopausal osteoporosis. Osteoporos Int 18 (2007) 1211-1218 [Epub 2007 May 22]
73. Delmas P.D., Bjarnason N.H., Mitlak B.H., Ravoux A.C., Shah A.S., Huster W.J., et al. Effects of raloxifène on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med 337 (1997) 1641-1647
74. Chen P., Satterwhite J.H., Licata A.A., Lewiecki E.M., Sipos A.A., Misurski D.M., et al. Early changes in biochemical markers of bone formation predict BMD response to teriparatide in postmenopausal women with osteoporosis. J Bone Miner Res 20 (2005) 962-970
75. Grados F., Brazier M., Kamel S., Mathieu M., Hurtebize N., Maamer M., et al. Prediction of bone density variation by bone remodeling markers in postmenopausal women with vitamin D insufficiency treated with calcium and vitamin D supplementation. J Clin Endocrinol Metab 11 (2003) 5175-5179
76. Delmas P.D. Markers of bone turnover for monitoring treatment of osteoporosis with antiresorptive drugs. Osteoporos Int Suppl. 6 (2000) S66-S76
77. Bjarnason N.H., Christiansen C., Sarkar S., Mitlak B., Delmas P.D., Christiansen C., and for the MORE Study Group. Six months changes in biochemical markers predict three-year response in vertebral fracture rate in postmenopausal, osteoporotic women: results from the MORE study. Osteoporos Int 12 (2001) 922-930
78. Li Z., Meredith M.P., and Hoseyni M.S. A method to assess the proportion of treatment effect explained by a surrogate endpoint. Stat Med 20 (2002) 3175-3188
79. Sarkar S., Mitlak B.H., Wong M., Stock J.L., Black D.M., and Harper K.D. Relationships between bone mineral density and incident fracture risk with raloxifene therapy. J Bone Miner Res 17 (2002) 1-10
80. Eastell R., Barton I., Hannon R.A., Chines A., Garnero P., and Delmas P.D. Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate. J Bone Miner 18 (2003) 1051-1056
81. Reginster J.Y., Sarkar S., Zegels B., Henrotin Y., Bruyere O., Agnusdei D., et al. Reduction in PINP, a marker of bone metabolism, with raloxifene treatment and its relationship with vertebral fracture risk. Bone 34 (2004) 344-351
82. Bauer D.C., Black D.M., Garnero P., Hochberg M., Ott S., Orloff J., et al. Change in bone turnover and hip, non-spine, and vertebral fracture in alendronate-treated women: the fracture intervention trial. J Bone Miner Res 19 (2004) 1250-1258
83. Meunier P.J., Roux C., Seeman E., Ortolani S., Badurski J.E., Spector T.D., et al. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 350 (2004) 459-468